Antiplatelet and anticoagulant use after myocardial infarction

被引:23
作者
Almony, GT
Lefkovits, J
Topol, EJ
机构
[1] Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH
[2] Department of Cardiology, One Clinic Center, Cleveland Clinic Foundation, Cleveland
关键词
antiplatelets; antithrombins; aspirin; GPIIb/IIIa; heparin; hirudin; myocardial infarction; warfarin;
D O I
10.1002/clc.4960190506
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Coronary thrombosis leading to myocardial infarction is a complex process involving the interaction of the arterial wall, the coagulation cascade, and platelets. Increased understanding of the molecular biology of thrombosis has prompted an evolution in antithrombotic therapy, from the early use of warfarin following myocardial infarction to agents targeting specific receptors or modulators in the thrombotic process. The complexity of thrombosis allows for numerous sites of pharmacologic intervention; the multiple pathways leading to platelet aggregation and thrombin formation provide the opportunity for combined therapies. This review presents the current clinical data on antiplatelet, anticoagulant, and specific antithrombin therapies following myocardial infarction.
引用
收藏
页码:357 / 365
页数:9
相关论文
共 109 条
  • [71] COLLAGENOUS PROTEINS OF BLOOD-VESSELS
    MAYNE, R
    [J]. ARTERIOSCLEROSIS, 1986, 6 (06): : 585 - 593
  • [72] THE THROMBOPLASTIC ACTION OF CEPHALIN
    McLean, Jay
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1916, 41 (02): : 250 - 257
  • [73] ASPIRIN VERSUS COUMADIN IN THE PREVENTION OF REOCCLUSION AND RECURRENT ISCHEMIA AFTER SUCCESSFUL THROMBOLYSIS - A PROSPECTIVE PLACEBO-CONTROLLED ANGIOGRAPHIC STUDY - RESULTS OF THE APRICOT STUDY
    MEIJER, A
    VERHEUGT, FWA
    WERTER, CJPJ
    LIE, KI
    VANDERPOL, JMJ
    VANEENIGE, MJ
    [J]. CIRCULATION, 1993, 87 (05) : 1524 - 1530
  • [74] MORICE MC, 1994, CIRCULATION, V90, P125
  • [75] SAFETY OBSERVATIONS FROM THE PILOT PHASE OF THE RANDOMIZED R-HIRUDIN FOR IMPROVEMENT OF THROMBOLYSIS (HIT-III) STUDY - A STUDY OF THE ARBEITSGEMEINSCHAFT-LEITENDER-KARDIOLOGISCHER-KRANKENHAUSARZTE (ALKK)
    NEUHAUS, KL
    VONESSEN, R
    TEBBE, U
    JESSEL, A
    HEINRICHS, H
    MAURER, W
    DORING, W
    HARMJANZ, D
    KOTTER, V
    KALHAMMER, E
    SIMON, H
    HORACEK, T
    [J]. CIRCULATION, 1994, 90 (04) : 1638 - 1642
  • [76] COMBINATION OF PLATELET FIBRINOGEN RECEPTOR ANTAGONIST AND DIRECT THROMBIN INHIBITOR AT LOW-DOSES MARKEDLY IMPROVES THROMBOLYSIS
    NICOLINI, FA
    LEE, P
    RIOS, G
    KOTTKEMARCHANT, K
    TOPOL, EJ
    [J]. CIRCULATION, 1994, 89 (04) : 1802 - 1809
  • [77] OHMAN EM, 1994, CIRCULATION, V90, P564
  • [78] PARISE LV, 1985, J BIOL CHEM, V260, P698
  • [79] PATRONO C, 1994, NEW ENGL J MED, V330, P1287
  • [80] PLOW EF, 1989, PROG HEMOST THROMB, V9, P117